泰国III期结肠癌患者辅助化疗的成本效用分析。
Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
作者信息
Lerdkiattikorn Panattharin, Chaikledkaew Usa, Lausoontornsiri Wirote, Chindavijak Somjin, Khuhaprema Thirawud, Tantai Narisa, Teerawattananon Yot
机构信息
Department of Pharmacy, Faculty of Medicine, Siriraj Hospital, 2 Prannok road, Siriraj, Bangkoknoi, Bangkok, Thailand 10700.
出版信息
Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):687-700. doi: 10.1586/14737167.2015.972379. Epub 2014 Oct 18.
BACKGROUND
In Thailand, there has been no economic evaluation study of adjuvant chemotherapy for stage III colon cancer patients after resection.
OBJECTIVE
This study aims to evaluate the cost-utility of all chemotherapy regimens currently used in Thailand compared with the adjuvant 5-fluorouracil/leucovorin (5-FU/LV) plus capecitabine as the first-line therapy for metastatic disease in patients with stage III colon cancer after resection.
METHODS
A cost-utility analysis was performed to estimate the relevant lifetime costs and health outcomes of chemotherapy regimens based on a societal perspective using a Markov model.
RESULTS
The results suggested that the adjuvant 5-FU/LV plus capecitabine as the first-line therapy for metastatic disease would be the most cost-effective chemotherapy.
CONCLUSIONS
The adjuvant FOLFOX and FOLFIRI as the first-line treatment for metastatic disease would be cost-effective with an incremental cost-effectiveness ratio of 299,365 Thai baht per QALY gained based on a societal perspective if both prices of FOLFOX and FOLFIRI were decreased by 40%.
背景
在泰国，尚未有关于III期结肠癌患者术后辅助化疗的经济学评估研究。
目的
本研究旨在评估泰国目前使用的所有化疗方案的成本效益，并与辅助性5-氟尿嘧啶/亚叶酸钙（5-FU/LV）加卡培他滨作为III期结肠癌切除术后转移性疾病的一线治疗方案进行比较。
方法
采用马尔可夫模型，从社会角度进行成本效益分析，以估计化疗方案的相关终生成本和健康结果。
结果
结果表明，辅助性5-FU/LV加卡培他滨作为转移性疾病的一线治疗方案将是最具成本效益的化疗方案。
结论
如果FOLFOX和FOLFIRI的价格均降低40%，从社会角度来看，辅助性FOLFOX和FOLFIRI作为转移性疾病的一线治疗方案将具有成本效益，每获得一个质量调整生命年的增量成本效益比为299,365泰铢。
Zotero 插件